tesa Labtec biedt nieuwe licentiemogelijkheid aan: transdermale pleister met ropivacaïne tegen neuropatische pijn
LANGENFELD, Duitsland–(BUSINESS WIRE)- De Duitse pleister- en folieproducent stelt zijn formule voor transdermale pleisters met ropivacaïne beschikbaar. De pleister is bedoeld voor de bestrijding van neuropatische pijn.
tesa heeft een matrixpleister met de lokale pijnstiller ropivacaïne (3 procent) ontwikkeld. De pleister is direct aan te brengen op de pijnlijke plek en zorgt minstens 24 uur voor pijnverlichting. De beoogde primaire indicatie van de pleister is postherpetische neuralgie. Daarnaast kan de pleister worden ingezet tegen andere indicaties, zoals chronische neuralgie, pijnlijke zweren in het been, brandende pijn, diabetische neuropatische pijn en chronische pijn in de onderrug.
tesa Labtec Offers New Licensing Opportunity: Ropivacaine Transdermal Patch for the Treatment of Neuropathic Pain |
|||||
|
LANGENFELD, Germany–(BUSINESS WIRE)– The German patch and thin-film maker announces the availability of a ropivacaine transdermal patch formulation for the treatment of neuropathic pain. tesa has developed a matrix patch containing the local anesthetic ropivacaine (3%). The patch is applied directly to the affected area and should deliver long-lasting pain relief for at least 24 hours. The targeted primary indication is post-herpetic neuralgia (PHN). However, additional indications such as other chronic neuralgias, painful non-healing leg ulcers, burn pain, diabetic neuropathy and chronic lower back pain could also be addressed. Existing market products require a higher dose and can only be worn for 12 hours, resulting in discontinuous treatment. tesa’s product provides a lower dose, which reduces the risk of systemic toxicity and makes application for 24 hours or longer possible. Further patient benefits include gentle patch adhesion, trauma-free removal and no detachment problems. The contract development and manufacturing organization (CDMO) has filed a PCT application for the product that is intended to protect its innovative formulation approach for the transdermal patch. tesa is endeavoring to find a product partner in order to continue the development of the patch by accomplishing a proof of concept study and executing a phase II study. Interested pharmaceutical companies are invited to meet tesa’s representatives at CPHI North America in Philadelphia (May 16-18) or at BIO International in San Diego (June 19-22). About tesa Labtec tesa Labtec undertakes the development and manufacture of film-shaped dosage forms (CDMO services) such as transdermal and topical patches as well as oral, buccal or sublingual films. Business activities comprise formulation development, scale-up and manufacture of clinical trial supplies or finished products under full cGMP conditions. tesa relies on its proprietary technologies, Transfilm ®, Rapidfilm ® and Mucofilm ®, for this. tesa Labtec is a wholly owned subsidiary of tesa SE, a member of the Beiersdorf group of companies, and represents the pharmaceutical business in a truly global family of companies. View source version on businesswire.com: http://www.businesswire.com/news/home/20170509005922/en/ Contacts tesa Labtec GmbH |
|||||